Profile: BioInvent International AB is a research-based pharmaceutical company developing antibody drugs for the treatment of cancer, thrombosis and atherosclerosis. Our TB-402 is a humanised monoclonal antibody that targets factor VIII, a blood clotting factor, and it is being developed as an anti-coagulant, to prevent deep vein thrombosis in connection with orthopaedic surgery & to prevent stroke in patients with atrial fibrillation. Our BI-204 is a human antibody which targets the oxidized form of a low-density lipoprotein, called apoB100, and it is being developed as a treatment for atherosclerosis, aimed at reducing the occurrence of heart attacks in high-risk patients.